undamentalytics Newsletter
Sign in

Rapid Micro Biosystems, Inc. (RPID) stock

Add to watchlist

Add holding +

NASDAQ: RPID Nasdaq Life Sciences Tools & Services Next results ~November 6, 2026

D Fundamentals grade

Rapid Micro Biosystems, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$3.1

Forward price-to-sales vs peers

Base case. Range ~$2.3–$6.8. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Rapid Micro Biosystems, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
  • Funds14 adding, 28 cuttingOf 11 active managers that changed their stake, 4 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Rapid Micro Biosystems files

Where Rapid Micro Biosystems stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $35m, up 16.1% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin rose to -114.8% from -126.4% a year earlier. Operating margin widened to -141.5% from -152.1%. The diluted share count is up 4.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 7 financial-health checks. Our price-to-sales vs peers value is $1.78 a share, against a share price of $0.78.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

Rapid Micro Biosystems, Inc.'s trailing-twelve-month revenue grew 16.1% year on year, with a free-cash-flow margin of -114.8%. Where it lags: net margin of -145.6% ranks 47 of 54 life sciences tools & services companies we cover.

Current signal Operating margin expanding: TTM operating margin reached -141.5%, up 10.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 16.1% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Margins widening. Operating margin is up 10.7 points on a year ago.

Things to watch

  • Loss-making. Operating margin is -141.5%: costs exceed revenue.
  • Burning cash. Free cash flow was -114.8% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 4.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 1.7 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$0.27 against an average estimate of -$0.24: missed by 11.0%
Revenue
$8m, up 10.9% on a year earlier
Share reaction
-17.8% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Next report
November 6, 2026; average EPS estimate -$0.20

Rapid Micro Biosystems' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.5%
  • 1 week-10.4%
  • 1 month-23.6%
  • This year-75.8%
  • 1 year-76.5%
  • 5 years-96.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$35.2M
Operating margin
-141.5%
Net margin
-145.6%
EPS (TTM, diluted)
$-1.11

Growth

Revenue growth
+16.1%
Change in growth rate
+0.1 pts
Share count change
+4.4%

Cash

Free cash flow (TTM)
-$40.4M
FCF margin
-114.8%
Stock pay % of revenue
12.3%

Earnings

Last results
August 7, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Rapid Micro Biosystems, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Rapid Micro Biosystems, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$3.1 ~$2.3–$6.8 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.1 ~$2.3–$6.8 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rapid Micro Biosystems, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$10.64$1.13$0.74$0.90$2.90$0.70
Market value$210m$48m$32m$39m$130m$32m
+ Net debt (− = net cash)−$178m−$27m−$24m−$17m−$1m$4m
Enterprise value$32m$21m$8m$22m$128m$37m
Multiples
Price / sales 9.1x2.8x1.4x1.4x3.9x0.9x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Rapid Micro Biosystems's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -42.3% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -197.4%; its worst year was -334.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -182.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 6, 2026, before the open. Analysts expect revenue of $10m and EPS of −$0.20 (range −$0.21 to −$0.19) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.94 +10% $39m +17%
Next −$0.71 +24% $46m +18%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.3% on 90 days ago. In the last 30 days, 1 analyst raised Rapid Micro Biosystems, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Rapid Micro Biosystems, Inc., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.93 Current fiscal year, 60 days ago: −$0.93 Current fiscal year, 30 days ago: −$0.94 Current fiscal year, 7 days ago: −$0.94 Current fiscal year, Now: −$0.94 −$0.94 Next fiscal year, 90 days ago: −$0.79 Next fiscal year, 60 days ago: −$0.79 Next fiscal year, 30 days ago: −$0.73 Next fiscal year, 7 days ago: −$0.73 Next fiscal year, Now: −$0.71 −$0.71

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.93−$0.79
60 days ago −$0.93−$0.79
30 days ago −$0.94−$0.73
7 days ago −$0.94−$0.73
Now −$0.94−$0.71

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.24 −$0.27 −11.0%
Mar 2026 −$0.25 −$0.31 −25.7%
Dec 2025 −$0.23 −$0.28 −23.5%
Sept 2025 −$0.24 −$0.26 −6.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202644

Counts of recommendations published by analysts covering Rapid Micro Biosystems, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.9%
of tradable shares
Days to cover
2.9
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
47%
of shares
Held by insiders
10.1%
of shares
Employees
171
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −76.5%

$2.99 on October 31, 2025 to $0.70

ThenNowEffect
Revenue (last 12 months) $30m $35m +16.1%
P/S multiple 4.3x 0.9x −78.9%
Share count 44m 46m −4.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −35.5%

$1.09 on November 3, 2023 to $0.70

ThenNowEffect
Revenue (last 12 months) $19m $35m +83.7%
P/S multiple 2.4x 0.9x −62.2%
Share count 43m 46m −7.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
RPID−89%−35%+22%+222%−76%
Industry peers (median)−51%−3%−15%−7%+16%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
RPID8%42%58%50%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
RPID−90%−51%−45%−49%−85%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 15, 2021: 98% from August 5, 2021 to July 3, 2024. Getting back needed a 4013% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.70 – $4.68
From 52-week high
−85.0%
vs 50-day average
−34.6%
vs 200-day average
−68.4%
Volatility (1 year)
81%
Beta vs S&P 500
1.74

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±16.3%
After a week
6 up, 6 down
typical move ±30.0%
After a month
5 up, 7 down
typical move ±45.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 −17.8% +0.6% −19.2% −41.3%
May 13, 2026 −10.1% +1.4% −22.1% −31.8%
March 12, 2026 −35.4% −2.1% −42.9% −51.4%
January 13, 2026 +19.9% −0.7% +50.2% +23.9%
November 7, 2025 +17.8% +1.7% +53.1% +41.1%
August 12, 2025 −10.7% +1.4% −24.5% −10.1%
May 9, 2025 +19.2% +3.2% +31.0% +46.5%
February 28, 2025 −21.9% −0.2% −27.8% −20.2%
January 14, 2025 +15.0% +2.0% +28.2% +224.5%
November 1, 2024 0.0% +0.2% +16.7% −3.7%
August 2, 2024 +16.4% −4.7% +25.4% +22.9%
May 3, 2024 −11.4% +2.3% −19.2% −24.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Rapid Micro Biosystems, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Rapid Micro Biosystems, Inc.
$20M $25M $30M $35M $40M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $20.6M Revenue (TTM), FY23 Q4: $22.5M Revenue (TTM), FY24 Q1: $23.1M Revenue (TTM), FY24 Q2: $24.7M Revenue (TTM), FY24 Q3: $26.2M Revenue (TTM), FY24 Q4: $28.1M Revenue (TTM), FY25 Q1: $29.6M Revenue (TTM), FY25 Q2: $30.3M Revenue (TTM), FY25 Q3: $30.5M Revenue (TTM), FY25 Q4: $33.6M Revenue (TTM), FY26 Q1: $34.4M Revenue (TTM), FY26 Q2: $35.2M $35.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $20.6M
FY23 Q4 $22.5M
FY24 Q1 $23.1M
FY24 Q2 $24.7M
FY24 Q3 $26.2M
FY24 Q4 $28.1M
FY25 Q1 $29.6M
FY25 Q2 $30.3M
FY25 Q3 $30.5M
FY25 Q4 $33.6M
FY26 Q1 $34.4M
FY26 Q2 $35.2M
Revenue growth, TTM YoY Rapid Micro Biosystems, Inc.
10% 15% 20% 25% 30% 35% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 14.4% Revenue growth, TTM YoY, FY23 Q4: 31.4% Revenue growth, TTM YoY, FY24 Q1: 28.2% Revenue growth, TTM YoY, FY24 Q2: 29.0% Revenue growth, TTM YoY, FY24 Q3: 27.3% Revenue growth, TTM YoY, FY24 Q4: 24.6% Revenue growth, TTM YoY, FY25 Q1: 28.4% Revenue growth, TTM YoY, FY25 Q2: 22.6% Revenue growth, TTM YoY, FY25 Q3: 16.6% Revenue growth, TTM YoY, FY25 Q4: 19.7% Revenue growth, TTM YoY, FY26 Q1: 16.0% Revenue growth, TTM YoY, FY26 Q2: 16.1% 16.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 14.4%
FY23 Q4 31.4%
FY24 Q1 28.2%
FY24 Q2 29.0%
FY24 Q3 27.3%
FY24 Q4 24.6%
FY25 Q1 28.4%
FY25 Q2 22.6%
FY25 Q3 16.6%
FY25 Q4 19.7%
FY26 Q1 16.0%
FY26 Q2 16.1%
Operating margin (TTM) Rapid Micro Biosystems, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -299.8% Operating margin (TTM), FY23 Q4: -251.2% Operating margin (TTM), FY24 Q1: -242.3% Operating margin (TTM), FY24 Q2: -219.7% Operating margin (TTM), FY24 Q3: -198.2% Operating margin (TTM), FY24 Q4: -178.0% Operating margin (TTM), FY25 Q1: -159.6% Operating margin (TTM), FY25 Q2: -152.1% Operating margin (TTM), FY25 Q3: -148.8% Operating margin (TTM), FY25 Q4: -141.1% Operating margin (TTM), FY26 Q1: -144.2% Operating margin (TTM), FY26 Q2: -141.5% -141.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -299.8%
FY23 Q4 -251.2%
FY24 Q1 -242.3%
FY24 Q2 -219.7%
FY24 Q3 -198.2%
FY24 Q4 -178.0%
FY25 Q1 -159.6%
FY25 Q2 -152.1%
FY25 Q3 -148.8%
FY25 Q4 -141.1%
FY26 Q1 -144.2%
FY26 Q2 -141.5%
FCF margin (TTM) Rapid Micro Biosystems, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -240.7% FCF margin (TTM), FY23 Q4: -208.4% FCF margin (TTM), FY24 Q1: -197.4% FCF margin (TTM), FY24 Q2: -189.2% FCF margin (TTM), FY24 Q3: -173.6% FCF margin (TTM), FY24 Q4: -162.3% FCF margin (TTM), FY25 Q1: -130.9% FCF margin (TTM), FY25 Q2: -126.4% FCF margin (TTM), FY25 Q3: -126.4% FCF margin (TTM), FY25 Q4: -95.0% FCF margin (TTM), FY26 Q1: -110.5% FCF margin (TTM), FY26 Q2: -114.8% -114.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -240.7%
FY23 Q4 -208.4%
FY24 Q1 -197.4%
FY24 Q2 -189.2%
FY24 Q3 -173.6%
FY24 Q4 -162.3%
FY25 Q1 -130.9%
FY25 Q2 -126.4%
FY25 Q3 -126.4%
FY25 Q4 -95.0%
FY26 Q1 -110.5%
FY26 Q2 -114.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 16 23 17 23 28 34 35
EBITDA −29 −46 −60 −53 −47 −44 −47
Operating income −31 −47 −63 −57 −50 −47 −50
Net income −37 −74 −61 −52 −47 −47 −51
Diluted EPS −$126.11 −$3.94 −$1.43 −$1.22 −$1.08 −$1.05 −$1.11
Growth (year on year)
Revenue — +44.5% −26.3% +31.4% +24.6% +19.7% +16.1%
Margins
EBITDA margin −180.6% −196.7% −352.4% −237.4% −166.0% −131.4% −133.0%
Operating margin −190.0% −203.3% −369.0% −251.2% −178.0% −141.1% −141.5%
Net margin −230.6% −316.5% −354.9% −233.0% −167.2% −140.3% −145.6%
Free-cash-flow margin −197.1% −250.4% −381.1% −208.4% −162.3% −95.0% −114.8%
Cash flow
Cash from operations −31 −55 −59 −45 −44 −31 −40
Capital spending 1 3 7 2 1 1 0
Free cash flow −32 −58 −65 −47 −46 −32 −40
Stock-based pay 1 2 4 5 4 4 4
Free cash flow after stock pay −32 −60 −69 −52 −49 −36 −45
Balance sheet
Cash 30 178 27 24 17 20 15
Total debt 25 0 0 0 0 19 19
Net debt (negative = net cash) −5 −178 −27 −24 −17 −1 4
Diluted shares — 20m 42m 43m 44m 45m 46m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $58m
Short-term assets $46mLonger-term assets $12m
What it owes, and who funded it · $58m
Short-term liabilities $18mLonger-term liabilities $23mShareholders' equity $18m
  • Short-term assets cover short-term liabilities $46m of assets due within a year against $18m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $46m short-term assets against $23m of longer-dated liabilities.
  • More cash than debt $15m of cash against $19m of debt.
  • Debt below 40% of shareholders' equity Debt is 108% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 108% over five years.
  • A year's operating cash flow covers at least 20% of debt −$40m of operating cash flow against $19m of debt.
  • Operating profit covers interest at least five times over Operating income of −$50m against $2m of interest.

From Rapid Micro Biosystems, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.4%
year over year
R&D spending
38.2%
of revenue
Days sales outstanding
57 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated RPID MXCT OABI BNGO TKNO CSBR Median
Revenue, last 12 months $35m $31m $40m $30m $44m $61m $229m
Revenue growth, last 12 months 16.1% −13.2% 90.6% 10.0% 12.3% 6.7% 6.9%
Revenue growth, 3-year average 22.5% −8.6% −14.7% −1.4% 3.7% 4.8% 2.9%
Revenue growth, latest quarter 10.9% −14.5% 78.3% 21.4% 18.5% 8.8% 8.5%
Gross margin — 79.2% — 47.5% 34.6% 49.8% 51.9%
Operating margin −141.5% −134.6% −115.9% −106.7% −36.2% −1.7% −14.3%
Operating margin, 3-year average −171.1% −128.7% −278.2% −293.0% −61.6% −1.2% −22.4%
Net margin −145.6% −114.8% −108.1% −106.6% −38.4% −1.8% −16.1%
Cash from operations / revenue −113.9% −74.0% 6.6% −67.9% −14.4% −9.2% 1.3%
Free-cash-flow margin −114.8% −76.1% 5.9% −67.9% −16.8% −10.1% −2.2%
Free-cash-flow margin, 3-year average −143.5% −79.7% −130.3% −150.1% −32.0% −0.4% 0.6%
Stock pay / revenue 12.3% 16.0% 32.7% 11.6% 6.7% 3.0% 4.4%
Change in share count 4.4% 1.0% 19.2% — 1.0% −2.4% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 16.1% 6.9% 15 of 54
Change in growth rate Growth +0.1pp +0.4pp 29 of 54
Operating margin Profitability -141.5% -14.3% 45 of 52
Net margin Profitability -145.6% -12.2% 47 of 54
Free-cash-flow margin Cash generation -114.8% -1.3% 47 of 54
Stock pay as % of revenue Cash generation 12.3% 4.4% 38 of 53
Long-term debt as % of assets Balance sheet 32.7% 26.3% 24 of 35
Change in share count Balance sheet 4.4% 1.0% 36 of 46
Days sales outstanding Balance sheet 57 days 62 days 21 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $23.4M 69.7% ▲ 25.1%
Services $10.2M 30.3% ▲ 9.0%
Geography
Region Revenue Share YoY
United States $13.4M 40.0% ▲ 26.3%
Switzerland $6M 17.9% ▲ 6.2%
All Other Countries $5.8M 17.2% ▼ 13.1%
Germany $5.8M 17.2% ▲ 89.2%
Japan $2.6M 7.7% ▲ 26.4%

From Rapid Micro Biosystems, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$30.1M
Institutions reporting
33
Shares held vs prior quarter
▲ 11.8%
Positions opened / closed
5 / 16

Top buyers and sellers, Q2 2026: 14 institutions bought and 28 sold ; the biggest buyer was Armistice Capital, LLC (+3.3M shares) and the biggest seller Essex Investment Management Co LLC (−521K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Bain Capital Life Sciences Investors, LLC $14.6M 8.4M 48.5% 0.0%
Armistice Capital, LLC $5.8M 3.3M 19.1% New
Abg-Wtt Global Life Science Capital Partners Gp Ltd $3.2M 1.8M 10.6% 0.0%
Vanguard Capital Management LLC $1.7M 982K 5.6% 0.0%
Evernest Financial Advisors, LLC $875,380 506K 2.9% ▲ 17.0%
Advent International, L.P. $657,044 380K 2.2% ▼ 31.2%
Essex Investment Management Co LLC $627,464 363K 2.1% ▼ 59.0%
Millennium Management LLC $409,316 237K 1.4% ▼ 16.5%
Geode Capital Management, LLC $394,706 228K 1.3% ▼ 7.7%
Renaissance Technologies LLC $366,935 212K 1.2% ▲ 67.5%
Blackrock, Inc. $328,410 190K 1.1% ▲ 20.7%
Vanguard Fiduciary Trust Co $191,137 110K 0.6% ▲ 0.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Rapid Micro Biosystems, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $1.1M 14 trades by 5 insiders · 0% under pre-set plans
Net ▼ $1.1M net selling
Insider Date Trade Shares Price Value
Wirtjes Sean M CHIEF FINANCIAL OFFICER March 11, 2026 Sell 7,480 $4.32 $32,314
Wilson John J. Addington CHIEF OPERATING OFFICER March 11, 2026 Sell 9,603 $4.32 $41,485
Spignesi Robert G. Jr. PRESIDENT AND CEO March 10, 2026 Sell 17,922 $4.11 $73,659
Wirtjes Sean M CHIEF FINANCIAL OFFICER February 20, 2026 Sell 17,254 $3.92 $67,636
Wilson John J. Addington CHIEF OPERATING OFFICER February 20, 2026 Sell 5,403 $3.92 $21,180
Spignesi Robert G. Jr. PRESIDENT AND CEO February 19, 2026 Sell 38,327 $3.89 $149,092
Spignesi Robert G. Jr. PRESIDENT AND CEO February 9, 2026 Sell 12,840 $3.78 $48,535
Wirtjes Sean M CHIEF FINANCIAL OFFICER February 9, 2026 Sell 6,027 $3.78 $22,782
Wilson John J. Addington CHIEF OPERATING OFFICER February 9, 2026 Sell 4,610 $3.78 $17,426
Longitude Venture Partners Ii, L.P. 10% owner February 4, 2026 Sell 49,000 $3.88 $190,120
Longitude Prime Partners, Llc 10% owner February 3, 2026 Sell 27,500 $4.24 $116,600
Longitude Prime Partners, Llc 10% owner February 2, 2026 Sell 27,500 $4.25 $116,875

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 7, 2026
  • May 13, 2026
  • March 12, 2026
  • January 13, 2026
  • November 7, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Rapid Micro Biosystems, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Rapid Micro Biosystems, Inc. in brief

What does Rapid Micro Biosystems, Inc. do?
Rapid Micro Biosystems, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Rapid Micro Biosystems, Inc.'s stock ticker?
Rapid Micro Biosystems, Inc. trades under the ticker RPID on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Rapid Micro Biosystems, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Rapid Micro Biosystems, Inc. reported revenue of $35.2M, 16.1% higher than a year earlier, according to its SEC filings.
What is Rapid Micro Biosystems, Inc.'s free cash flow?
Rapid Micro Biosystems, Inc.'s free-cash-flow margin is -114.8% of revenue over the trailing twelve months, ranking 47 of the 54 life sciences tools & services companies we cover.
Who are Rapid Micro Biosystems, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Bain Capital Life Sciences Investors, LLC, Armistice Capital, LLC and Abg-Wtt Global Life Science Capital Partners Gp Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Rapid Micro Biosystems, Inc.'s market cap?
On November 2, 2026, Rapid Micro Biosystems, Inc.'s market capitalisation was about $32.3M and net debt of $4.5M. Market figures come from third-party market data and may be delayed.
How much debt does Rapid Micro Biosystems, Inc. have?
Rapid Micro Biosystems, Inc.'s debt-to-equity ratio is 107.8%, from its latest balance sheet (0.0% five years earlier). The financial health section below sets out its other solvency checks.
Who are Rapid Micro Biosystems, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Rapid Micro Biosystems, Inc. are Maxcyte, Inc., Omniab, Inc., Bionano Genomics, Inc., Alpha Teknova, Inc. and Champions Oncology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Rapid Micro Biosystems, Inc.'s.
Are insiders buying or selling Rapid Micro Biosystems, Inc. stock?
Over the last 12 months, Rapid Micro Biosystems, Inc.'s directors and officers reported 0 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Rapid Micro Biosystems, Inc.'s next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Rapid Micro Biosystems, Inc. announces its own schedule.